Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
sanofi hero cover image

Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) affects 1 in 5 females of reproductive age. Commonly characterized as a disorder of infertility, PCOS is often accompanied by 3 potent cardiovascular disease (CVD) risk factors: insulin resistance, endothelial dysfunction, and elevated blood pressure. Accordingly, PCOS is associated with the development of CVD, the second leading cause of death in females in Canada. However, effective treatments to improve cardiovascular health in PCOS are lacking.

Exogenous ketone monoester (KME) ingestion has been shown to improves outcomes associated with insulin resistance, endothelial function, and blood pressure regulation in healthy individuals and individuals predisposed to CVD. Therefore, oral ketone supplements offer a practical and effective strategy for improving cardiovascular health; however, this treatment has yet to be evaluated in PCOS.

Therefore, the overall goal of this project is to employ KME ingestion to improve markers of cardiovascular health in females with PCOS.

On two different days, participants will consume either a beverage containing a ketone supplement or a beverage containing a placebo supplement. The objectives are to compare responses between KME and placebo ingestion, and examine all outcomes related to cardiovascular health in females with PCOS in comparison with female controls of similar age and body mass index. The effects of KME ingestion will be quantified on: 1) glycemic control during an oral glucose tolerance test; 2) endothelial function using the flow-mediated dilation test; 3) blood pressure and acute blood pressure regulation; and 4) hemodynamic responses to acute exercise.

Diabetes

What is Diabetes?
A large percentage of viewers are on mobile devices, so keep it short and to the point. Have you ever noticed how long a 5 sentence paragraph looks on a smart phone? If you read it via desktop/laptop, you realize it is really not that much information. A suggestion is to plan on “marrying” the two and keep the chatter down. Conversely, don’t sacrifice the “meat and potatoes” of what you’re trying to convey; this will help to keep the organic SEO strong.
What causes Diabetes?
Viewers need to be given a direction every now and then. Use your headers to draw the eye where you want it. Imagine the website as a term paper and your outline will guide your structure. Focus broad topics on the main headers and help guide the viewer down the right path! Appropriately introducing call-to-action buttons also helps with guiding the reader and connecting content writing with your website’s goal.
How is Diabetes treated?
Here are a few website content writing tips to make sure your website content gets the attention it deserves • Know your audience • Write short, simple sentences – Nix the jargon – Mix up your word choice • Make text scannable • Incorporate multimedia Capturing reader’s interests with good website content and information can be challenging. Most visitors will spend just a few seconds on a webpage, before deciding what to do next. Therefore, good website writing is the key to beating these odds.
More information about Diabetes
National Diabetes Foundation National Diabetes Foundation – Support Network American Academy of Diabetes International Diabetes Council International Federation of Diabetes Associations

Call 1800-9860-568 now to find out if you are eligible.

Patient image

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Patient image
Diabetes icon
Diabetes
A short sentence to introduce what to expect in the about condition section
Learn more
Study icon
The Study
A short sentence to introduce what to expect in the about condition section
Learn more
Clinical Trials icon
About Clinical Trials
A short sentence to introduce what to expect in the about condition section
Learn more

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Patient image
Patient image

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Patient image